Dear Editor,
We have read and reviewed the article 'Effect of Marijuana use on cardiovascular and cerebrovascular mortality: A study using the National Health and Nutrition Examination Survey linked mortality file' published online 8 August 2017. 1 Research on marijuana is challenging, given the fact that it is classified as a schedule I drug by the Drug Enforcement Agency. Because marijuana use is expanding rapidly for medicinal and recreational purposes, it is critical that analyses of population samples are carefully described. We are concerned that the report by Yankey and coworkers 1 may be misinterpreted by the journal readers.
Self-reported data on marijuana use were collected from adults who were part of the National Health and Nutrition Examination Survey (NHANES) from 2005. NHANES data are typically collected from a two year cycle, and reported as [2005] [2006] . Moreover, in an effort to maintain complex multistage sampling design of the survey data and to account for oversampling of certain groups and non-response bias, the use of sampling weighting is recommended.
2 Further, the authors do not clearly describe the process by which the mortality data and NHANES data are combined. For the NHANES data alone, only those aged 20-59 years of age were given the opportunity to report on drug use. The authors of the study report they used the question from this data set: ''Have you ever used marijuana or hashish?'' to which respondents answer ''Yes'' or ''No''. Length of use was then estimated by subtracting the respondent's current age from the age at which they ''first tried'' marijuana. This method creates a group in which past users of marijuana are lumped together with current users with no regard for frequency of use nor the last time marijuana was used. Examination of responses to the latter reveals that 1059 of the 1567 adults reporting the last time they used marijuana was ''years'' ago, a median of 13 years ago, and a range of 1-40 years. Authors reported the average duration of marijuana use from their sample was 11.5 years. However, this is not possible to ascertain from the drug use questions in NHANES data because one cannot assume continuous use from the way the NHANES questions are asked. It is more reasonable to say that age of first marijuana use is associated with an increased risk of death from cardiovascular mortality. It was also unclear how many participants who smoked cigarettes also reported using marijuana.
It is unclear why age was dichotomized. Authors report this is the age cutpoint for illicit drug use; however, age in and of itself is related to cardiovascular and cerebrovascular diseases. It is difficult to ascertain from the article if this was the cutpoint for age of first onset of marijuana use, or the participant's age during the 2005 NHANES data collection. It might be more meaningful to present the demographics of the analytic sample as a function of reported marijuana use (yes/no) and to further qualify this response either by incorporating frequency of use or last time used in this classification (DUQ200 and DUQ 220).
In order to assess the effects of marijuana use, marijuana use must be properly operationalized and appropriate sampling weight applied in the analyses. Investigating effects of marijuana is challenging; limitations including classification of marijuana use must be clearly described. It is difficult to ascertain the possible impact on mortality without a more explicit understanding of this marijuana user group. It is important to clarify whether the group includes a proportion of individuals who have not used marijuana for years, and then maybe once or twice. The classification of a marijuana user necessitates further examination. There are large assumptions made on the part of continued marijuana use which cannot be verified given the questions within the NHANES questionnaire. We urge caution in interpretation of this report.
